- Home
- UCAR vs KPRX Comparison
UCAR vs KPRX Comparison
Compare UCAR & KPRX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
Company Overview
Basic Information| Metric | UCAR | KPRX |
|---|---|---|
| Founded | 2013 | 1998 |
| Country | China | United States |
| Employees | N/A | N/A |
| Industry | Retail-Auto Dealers and Gas Stations | Biotechnology: In Vitro & In Vivo Diagnostic Substances |
| Sector | Consumer Discretionary | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 7.0M | 8.0M |
| IPO Year | 2022 | N/A |
Fundamental Metrics
Financial Performance| Metric | UCAR | KPRX |
|---|---|---|
| Price | $0.51 | $2.09 |
| Analyst Decision | Strong Buy | Strong Buy |
| Analyst Count | 1 | 1 |
| Target Price | $5.00 | ★ $10.00 |
| AVG Volume (30 Days) | ★ 73.4K | 24.5K |
| Earning Date | 01-01-0001 | 01-01-0001 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | N/A |
| EPS | N/A | N/A |
| Revenue | N/A | N/A |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | N/A | N/A |
| P/E Ratio | N/A | N/A |
| Revenue Growth | N/A | N/A |
| 52 Week Low | $0.55 | $1.76 |
| 52 Week High | $4.98 | $4.18 |
Technical Indicators
Market Signals| Indicator | UCAR | KPRX |
|---|---|---|
| Relative Strength Index (RSI) | 21.10 | 47.93 |
| Support Level | N/A | $1.96 |
| Resistance Level | $2.17 | $2.21 |
| Average True Range (ATR) | 0.11 | 0.09 |
| MACD | -0.10 | 0.01 |
| Stochastic Oscillator | 0.67 | 42.35 |
Price Performance
Historical ComparisonAbout UCAR U Power Limited
U Power Ltd is involved in the provision of vehicle sourcing services. It is principally engaged in the provision of new energy vehicles development and sales; battery swapping stations manufacturing and sales; battery swapping services, and sourcing services. The company, as a broker, engaged in sales of vehicles between automobile wholesalers and buyers, including small and medium-sized vehicle dealers and individual customers located in lower-tier cities in China.
About KPRX Kiora Pharmaceuticals Inc.
Kiora Pharmaceuticals Inc is a clinical-stage biotechnology company developing and commercializing products for the treatment of orphan retinal diseases. As part of its development, KIO-301 is being studied for the treatment of retinitis pigmentosa, choroideremia, and Stargardt disease. It is a molecular photoswitch that has the potential to restore vision in patients with inherited and/or age-related retinal degeneration. KIO-104 is being developed for the treatment of posterior non-infectious uveitis. It is a next-generation, non-steroidal, immuno-modulatory, and small-molecule inhibitor of dihydroorotate dehydrogenase.